by dyadic | Mar 18, 2021 | Press Releases
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from C1-cellsDYAI-100 generated high levels of neutralizing antibodies in preclinical...
by dyadic | Mar 16, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and...
by dyadic | Mar 9, 2021 | Press Releases
Results demonstrate that Dyadic’s C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trialsJUPITER, Fla., March 09, 2021 (GLOBE NEWSWIRE) — Dyadic International,...
by dyadic | Feb 15, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / February 15, 2021 / Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production...
by dyadic | Feb 3, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
by dyadic | Feb 2, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / February 2, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
